EMEA-002323-PIP02-19

Table of contents

Key facts

Active substance
Relamorelin
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0367/2020
PIP number
EMEA-002323-PIP02-19
Pharmaceutical form(s)
  • Age-appropriate oral dosage form
  • Solution for injection
Condition(s) / indication(s)
Treatment of gastroparesis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Allergan Pharmaceuticals International Limited

E-mail: ml-eu_reg_affairs@allergan.com
Tel. +44 (0)1628 4944444

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating